Experienced in Metastatic Brain Tumor

Carsten Grullich

Dresden, SN, DE 
Experienced in Metastatic Brain Tumor
Dresden, SN, DE 
OverviewLocationsClinical Research

Overview

Carsten Grullich practices in Dresden, Germany. Mr. Grullich is rated as an Experienced expert by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Choriocarcinoma, Familial Prostate Cancer, and Thrombectomy.

His clinical research consists of co-authoring 70 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Metastatic Brain Tumor.

Gender
Male

Locations

Dresden, SN, Germany
Other Locations
Heidelberg, BW, Germany
Lebach, SL, Germany
Freiburg, BW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2

70 Total Publications

Identification of genomic drivers for the therapeutic response of Cabozantinib in patients with metastatic renal cell carcinoma.
Identification of genomic drivers for the therapeutic response of Cabozantinib in patients with metastatic renal cell carcinoma.
Journal: World journal of urology
Published: August 06, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Grullich's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile